Verge Genomics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 76

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 35

Verge Genomics General Information

Description

Developer of a drug discovery platform intended to accelerate the development of life-saving treatments for neurodegenerative diseases. The company's platform utilizes machine learning to develop therapeutics, specifically for neurological diseases and can analyze datasets of any size to identify new targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2 Tower Place
  • Suite 940
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Verge Genomics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verge Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 20-Mar-2024 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 08-Sep-2023 0000 00000 00000 Completed Pre-Clinical Trials
3. Later Stage VC (Series B1) 15-Dec-2021 0000 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 16-Jul-2018 $32M $32.1M 0000 Completed Pre-Clinical Trials
1. Accelerator/Incubator 18-Aug-2015 $120K $120K 00.000 Completed Startup
To view Verge Genomics’s complete valuation and funding history, request access »

Verge Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A6 000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series A5 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A2 1,698,104 $0.000100 6% $2.65 $2.65 1x $2.65 3.26%
Series A1 13,622,216 $0.000100 6% $3.31 $3.31 1x $3.31 26.12%
To view Verge Genomics’s complete cap table history, request access »

Verge Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform intended to accelerate the development of life-saving treatments for neurodegener
Drug Discovery
South San Francisco, CA
76 As of 2024
00000
0000000000 0 00000

000000

um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proide
0000 000000000
Singapore, Singapore
00 As of 0000
00000
0000000000 0 00000

000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
Cambridge, MA
00 As of 0000
0000
00000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verge Genomics Competitors (56)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cerecin Venture Capital-Backed Singapore, Singapore 00 00000 0000000000 0 00000
Mitobridge Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
PAQ Therapeutics Venture Capital-Backed Cambridge, MA 0 0000 000000000000 0000
Alzheon Venture Capital-Backed Framingham, MA 00 00000 00000000000 00000
Atomwise Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
You’re viewing 5 of 56 competitors. Get the full list »

Verge Genomics Patents

Verge Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4118087-A1 Substituted furo[3,2-d]pyrimidines and uses thereof Pending 09-Mar-2020 00000000000
US-20230146395-A1 Substituted pyrimidines and uses thereof Pending 09-Mar-2020 00000000000
AU-2021207804-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 0000000000
EP-4090426-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 0000000000
US-20230133203-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 A61P21/00
To view Verge Genomics’s complete patent history, request access »

Verge Genomics Executive Team (11)

Name Title Board Seat
Alice Zhang Ph.D Co-Founder, Board Member & Chief Executive Officer
Jane Rhodes Ph.D Chief Business Officer & President
Robert Scannevin Ph.D Chief Scientific Officer
Michelle Mighdoll Director, Business Development & Corporate Strategy
Jason Chen MD Co-Founder & Advisor
You’re viewing 5 of 11 executive team members. Get the full list »

Verge Genomics Board Members (9)

Name Representing Role Since
Alfred Sandrock Jr. Self Board Member 000 0000
Alice Zhang Ph.D Verge Genomics Co-Founder, Board Member & Chief Executive Officer 000 0000
Andrew Allen Ph.D Self Board Member 000 0000
David Madge Ph.D WuXi AppTec Board Observer 000 0000
Emily Melton Threshold Ventures Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Verge Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verge Genomics Investors (35)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ferrer Internacional Corporation Minority 000 0000 000000 0
Alexion Corporation Minority 000 0000 000000 0
AstraZeneca Corporation Minority 000 0000 000000 0
Merck & Co. Corporation Minority 000 0000 000000 0
Tenmile Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 35 investors. Get the full list »

Verge Genomics FAQs

  • When was Verge Genomics founded?

    Verge Genomics was founded in 2015.

  • Who is the founder of Verge Genomics?

    Alice Zhang Ph.D and Jason Chen MD are the founders of Verge Genomics.

  • Who is the CEO of Verge Genomics?

    Alice Zhang Ph.D is the CEO of Verge Genomics.

  • Where is Verge Genomics headquartered?

    Verge Genomics is headquartered in South San Francisco, CA.

  • What is the size of Verge Genomics?

    Verge Genomics has 76 total employees.

  • What industry is Verge Genomics in?

    Verge Genomics’s primary industry is Drug Discovery.

  • Is Verge Genomics a private or public company?

    Verge Genomics is a Private company.

  • What is Verge Genomics’s current revenue?

    The current revenue for Verge Genomics is 000000.

  • How much funding has Verge Genomics raised over time?

    Verge Genomics has raised $172M.

  • Who are Verge Genomics’s investors?

    Ferrer Internacional, Alexion, AstraZeneca, Merck & Co., and Tenmile are 5 of 35 investors who have invested in Verge Genomics.

  • Who are Verge Genomics’s competitors?

    Cerecin, Mitobridge, PAQ Therapeutics, Alzheon, and Atomwise are some of the 56 competitors of Verge Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »